HIV heart risk: can two drug combos tame weight and cholesterol?
NCT ID NCT06317051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drug combinations in 300 people with HIV who have gained weight or have high cholesterol. One part compares dapagliflozin (a diabetes drug) to a placebo for weight loss. The other compares a two-drug statin combo to a single statin for lowering cholesterol. The goal is to reduce heart disease risk in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin, Rosuvastatin/Ezetimibe, Pitavastatin
What this could lead to
If successful, this could offer a way to manage weight and cholesterol in people with HIV, reducing their risk of heart disease.
What could go wrong
This is a mid-stage trial with 300 participants, so results may not apply to everyone. The drugs may cause side effects like muscle pain or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Melbourne, Victoria, 3084, Australia
-
CART-CRS
Chennai, Tamil Nadu, 600113, India
-
Desmond Tutu Health Foundation
Cape Town, 7925, South Africa
-
HIV-NAT
Bangkok, Thailand
-
Hospital Ramos Mejía
Buenos Aires, Argentina
-
Infectious Diseases Institute, Makerere University
Kampala, Uganda
-
Institute of Human Virology, Nigeria
Abuja, Nigeria
-
St Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
Universiti Malaya Medical Centre
Kuala Lumpur, Malaysia
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe